Andrew A. F. Hack, MD, PhD

Andrew is a Managing Director of Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally. Previously, Andrew served as Chief Financial Officer of Editas Medicine, Inc.

Prior to joining Editas, Andrew was a portfolio manager at Millennium Management LLC, where he ran a healthcare fund focused on biotechnology, pharmaceutical, and medical device companies. Before joining Millennium, Andrew served as a securities analyst for several healthcare-focused hedge funds and investment banks. Previously, Andrew was Director of Life Sciences of Reify Corporation, a life science tools and drug discovery company.

Andrew serves as a director of Affinivax, Inc., Allena Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc., BCLS Acquisition Corp., Dynavax Technologies, Inc., Imperative Care, Inc., JenaValve Technology, Inc., Mersana Therapeutics, Inc., and Xilio Therapeutics. Andrew received his M.D. and Ph.D. from the University of Chicago in molecular genetics and cell biology.